Beam Therapeutics Inc. (BMV:BEAM)

Market Cap	43.92B
Revenue (ttm)	1.14B
Net Income (ttm)	-7.52B
Shares Out	n/a
EPS (ttm)	-84.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	170
Average Volume	187
Open	450.37
Previous Close	411.07
Day's Range	443.50 - 450.37
52-Week Range	309.00 - 590.00
Beta	n/a
RSI	55.72
Earnings Date	Nov 5, 2025

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 483
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BEAM

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Financial numbers in USD